Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Dicerna Pharmaceuticals Inc. (DRNA)

14.33   0.13 (0.92%) 07-16 16:00
Open: 14.2 Pre. Close: 14.2
High: 14.46 Low: 14.16
Volume: 391,783 Market Cap: 979M

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 14.494 - 14.59 14.59 - 14.676
Low: 13.842 - 13.965 13.965 - 14.076
Close: 14.013 - 14.204 14.204 - 14.377

Technical analysis

as of: 2019-07-16 3:20:12 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 18.23     One year: 19.80
Support: Support1: 13.44    Support2: 11.18
Resistance: Resistance1: 15.61    Resistance2: 16.95
Pivot: 14.92
Moving Average: MA(5): 14.29     MA(20): 15.07
MA(100): 13.43     MA(250): 13.28
MACD: MACD(12,26): 0.08     Signal(9): 0.29
Stochastic oscillator: %K(14,3): 5.41     %D(3): 5.56
RSI: RSI(14): 45.56
52-week: High: 17.98  Low: 9.31  Change(%): 14.2
Average Vol(K): 3-Month: 40251  10-Days: 31690

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
DRNA has closed above bottom band by 22.9%. Bollinger Bands are 9.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 10 May 2019 02:55:25 Z
Dicerna Pharmaceuticals Inc (DRNA) Q1 2019 Earnings Call Transcript

Fri, 10 May 2019 00:55:59 Z
Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Lags Revenue Estimates

Thu, 11 Apr 2019 15:18:00 Z
4 Drug/Biotech Stocks Making a Mark in RNAi Therapeutics

Tue, 12 Mar 2019 03:07:06 Z
Dicerna Pharmaceuticals Inc (DRNA) Q4 2018 Earnings Conference Call Transcript

Tue, 12 Mar 2019 00:11:22 Z
Dicerna Pharmaceuticals (DRNA) Reports Q4 Loss, Lags Revenue Estimates

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 68.32
Shares Float (M) 43.97
% Held by Insiders 8.38
% Held by Institutions 91.35
Shares Short (K) 5060
Shares Short P. Month (K)

Stock Financials

EPS -1.660
EPS Est. Current Year -2.700
EPS Est. Next Year -2.760
EPS Est. Next Quarter -0.690
Forward EPS -1.640
Book Value (p.s.) 2.630
PEG Ratio
Profit Margin
Operating Margin -991.33
Return on Assets (ttm) -19.6
Return on Equity (ttm) -74.3
Qtrly Rev. Growth 101.1
Gross Profit (p.s.) -0.579
Sales Per Share
EBITDA (p.s.) -1.111
Qtrly Earnings Growth
Operating Cash Flow (M) 107.04
Levered Free Cash Flow (M) 21.09

Stock Valuations

P/E -8.58
P/E Growth Ratio
P/BV 5.42
P/S 7488923136.00
P/CF 9.10

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.